These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

231 related articles for article (PubMed ID: 33577782)

  • 1. Oncolytic Viruses for Systemic Administration: Engineering a Whole Different Animal.
    Atasheva S; Shayakhmetov DM
    Mol Ther; 2021 Mar; 29(3):904-907. PubMed ID: 33577782
    [No Abstract]   [Full Text] [Related]  

  • 2. Engineering Viruses to Fight Cancer.
    EBioMedicine; 2016 Jan; 3():1. PubMed ID: 26870830
    [No Abstract]   [Full Text] [Related]  

  • 3. Introduction to Oncolytic Virotherapy.
    Engeland CE; Bell JC
    Methods Mol Biol; 2020; 2058():1-6. PubMed ID: 31486028
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Gene therapy progress and prospects cancer: oncolytic viruses.
    Liu TC; Kirn D
    Gene Ther; 2008 Jun; 15(12):877-84. PubMed ID: 18418413
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Optimization and preclinical design of genetically engineered viruses for human oncolytic therapy.
    Hiss DC; Fielding BC
    Expert Opin Biol Ther; 2012 Nov; 12(11):1427-47. PubMed ID: 22788715
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Chapter four--Design of improved oncolytic adenoviruses.
    Alemany R
    Adv Cancer Res; 2012; 115():93-114. PubMed ID: 23021243
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Oncolytic virus therapy using genetically engineered herpes simplex viruses.
    Todo T
    Front Biosci; 2008 Jan; 13():2060-4. PubMed ID: 17981691
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Modification of oncolytic adenovirus and its application in cancer therapy.
    Liang Y; He J; Zhao Y
    Discov Med; 2020; 30(161):129-144. PubMed ID: 33593481
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The promise of microbial engineering for developing new strategies for tackling human disease.
    López-Goñi I
    Future Microbiol; 2012 Feb; 7(2):167-9. PubMed ID: 22324983
    [No Abstract]   [Full Text] [Related]  

  • 10. Oncolytic Immunotherapy.
    Hennessy ML; Bommareddy PK; Boland G; Kaufman HL
    Surg Oncol Clin N Am; 2019 Jul; 28(3):419-430. PubMed ID: 31079797
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Methods for the Construction of Recombinant Oncolytic Myxoma Viruses.
    Torres-Domínguez LE; de Matos AL; Rahman MM; McFadden G
    Methods Mol Biol; 2021; 2225():63-75. PubMed ID: 33108657
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting pediatric cancer stem cells with oncolytic virotherapy.
    Friedman GK; Cassady KA; Beierle EA; Markert JM; Gillespie GY
    Pediatr Res; 2012 Apr; 71(4 Pt 2):500-10. PubMed ID: 22430386
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Oncolytic viruses: immune or cytolytic therapy?
    Bell J
    Mol Ther; 2014 Jul; 22(7):1231-1232. PubMed ID: 24981435
    [No Abstract]   [Full Text] [Related]  

  • 14. Oncolytic viruses & their specific targeting to tumour cells.
    Singh PK; Doley J; Kumar GR; Sahoo AP; Tiwari AK
    Indian J Med Res; 2012 Oct; 136(4):571-84. PubMed ID: 23168697
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Virotherapy--cancer targeted pharmacology.
    Tedcastle A; Cawood R; Di Y; Fisher KD; Seymour LW
    Drug Discov Today; 2012 Mar; 17(5-6):215-20. PubMed ID: 22198165
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Potentiation of oncolytic virotherapy with armed shRNA.
    Guo W; Fang B
    Cancer Biol Ther; 2009 Jan; 8(1):92-3. PubMed ID: 19127117
    [No Abstract]   [Full Text] [Related]  

  • 17. Development of Group B Coxsackievirus as an Oncolytic Virus: Opportunities and Challenges.
    Liu H; Luo H
    Viruses; 2021 Jun; 13(6):. PubMed ID: 34198859
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Integrating oncolytic viruses in combination cancer immunotherapy.
    Bommareddy PK; Shettigar M; Kaufman HL
    Nat Rev Immunol; 2018 Aug; 18(8):498-513. PubMed ID: 29743717
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Armed interference: oncolytic viruses engineered to carry antitumor shRNAs.
    Kirn D
    Mol Ther; 2007 Feb; 15(2):227-8. PubMed ID: 17235298
    [No Abstract]   [Full Text] [Related]  

  • 20. Exploiting diversity: genetic approaches to creating highly potent and efficacious oncolytic viruses.
    Bauzon M; Hermiston TW
    Curr Opin Mol Ther; 2008 Aug; 10(4):350-5. PubMed ID: 18683099
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.